Table 5. Significant and novel pathways identified by our new method applied to “enhancer + gene body” regions, but missed by TWAS and STD, with the SCZ2 data.

ID	Pathway name	# gen	SPU(1)	SPU(2)	Source
hsa00071	Fatty acid degradation	42	$8.5\times {10}^{-1}$	$6.7\times {10}^{-5}$	Hippo
hsa00511	Other glycan degradation	15	$9.7\times {10}^{-5}$	$1.0\times {10}^{-3}$	Hippo
hsa00534	Glycosaminoglycan biosynthesis	26	$3.7\times {10}^{-1}$	$5.5\times {10}^{-5}$	Hippo
hsa03320	PPAR signaling	66	$6.6\times {10}^{-1}$	$6.9\times {10}^{-5}$	Hippo
hsa04621	NOD-like receptor signaling	57	$4.8\times {10}^{-1}$	$2.1\times {10}^{-5}$	Hippo
			$1.7\times {10}^{-2}$	$2.9\times {10}^{-5}$	MCF7
hsa04960	Aldosterone-regulated sodium reabsorption	40	$5.3\times {10}^{-1}$	$5.8\times {10}^{-6}$	Hippo
hsa04966	Collecting duct acid secretion	25	$1.1\times {10}^{-1}$	$3.0\times {10}^{-11}$	Hippo
hsa00562	Inositol phosphate metabolism	53	$7.0\times {10}^{-1}$	$7.4\times {10}^{-5}$	MCF7
hsa03022	Basal transcription factors	33	$3.0\times {10}^{-2}$	$4.7\times {10}^{-7}$	MCF7
hsa03450	Nonhomologous end-joining	13	$1.2\times {10}^{-1}$	$1.0\times {10}^{-5}$	MCF7
hsa05130	Pathogenic Escherichia coli infection	52	$8.3\times {10}^{-1}$	$3.0\times {10}^{-5}$	MCF7